Free Trial
→ Elon Musk’s next move from the Oval Office? (From Weiss Ratings) (Ad) Buy SLNO Stock  Free SLNO Stock Alerts

Soleno Therapeutics (SLNO) Financials

Soleno Therapeutics logo
$74.86 -0.41 (-0.54%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Soleno Therapeutics

Annual Income Statements for Soleno Therapeutics

This table shows Soleno Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -16 -16 -15 -13 -31 -25 -31 -24 -39 -176
Consolidated Net Income / (Loss)		 -16 -12 -15 -13 -31 -25 -31 -24 -39 -176
Net Income / (Loss) Continuing Operations		 -16 -6.74 -12 -12 -31 -25 -31 -24 -39 -176
Total Pre-Tax Income 		-16 -6.74 -13 -12 -31 -25 -31 -24 -39 -176
Total Operating Income		 -12 -8.32 -12 -14 -23 -36 -32 -24 -41 -188
Total Gross Profit		 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 12 8.32 12 14 23 36 32 24 41 188
Selling, General & Admin Expense		 6.14 6.08 6.58 6.56 6.93 8.76 11 9.84 13 106
Research & Development Expense		 4.54 2.25 3.07 7.18 16 23 21 15 25 79
Other Operating Expenses / (Income)		 - - 2.49 0.57 0.29 4.34 -0.73 -0.71 2.71 3.24
Total Other Income / (Expense), net		 -3.75 1.59 -1.27 2.46 -7.29 12 0.62 0.33 2.40 12
Interest Expense		 - - - - - - - 0.00 0.00 0.23
Interest & Investment Income		 - - - 1.83 -0.48 - - 0.30 2.58 12
Other Income / (Expense), net		 -3.75 1.59 -1.27 0.63 -6.81 12 0.62 0.03 -0.18 0.00
Basic Earnings per Share		 ($1.69) ($5.07) ($1.71) ($0.64) ($0.90) ($0.39) ($5.81) ($2.87) ($2.36) ($4.38)
Weighted Average Basic Shares Outstanding		 9.43M 3.10M 8.98M 20.98M 34.14M 62.62M 5.32M 8.40M 16.49M 40.18M
Diluted Earnings per Share		 ($1.69) ($5.07) ($1.71) ($0.64) ($0.90) ($0.39) ($5.81) ($2.87) ($2.36) ($4.38)
Weighted Average Diluted Shares Outstanding		 9.43M 3.10M 8.98M 20.98M 34.14M 62.62M 5.32M 8.40M 16.49M 40.18M
Weighted Average Basic & Diluted Shares Outstanding		 9.43M 3.10M 8.98M 20.98M 34.14M 62.62M 79.77M 8.17M 32.46M 45.86M

Quarterly Income Statements for Soleno Therapeutics

This table shows Soleno Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.13 -5.49 -8.36 -8.48 -11 -11 -21 -22 -77 -56
Consolidated Net Income / (Loss)		 -6.13 -5.49 -8.36 -8.48 -11 -11 -21 -22 -77 -56
Net Income / (Loss) Continuing Operations		 -6.13 -5.49 -8.36 -8.48 -11 -11 -21 -22 -77 -56
Total Pre-Tax Income 		-6.13 -5.49 -8.36 -8.48 -11 -11 -21 -22 -77 -56
Total Operating Income		 -6.24 -5.61 -8.47 -8.62 -10 -14 -23 -25 -80 -59
Total Operating Expenses		 6.24 5.61 8.47 8.62 10 14 23 25 80 59
Selling, General & Admin Expense		 2.33 2.40 2.85 3.17 3.32 4.14 8.47 11 49 37
Research & Development Expense		 3.77 3.81 5.32 5.14 6.04 8.69 15 12 30 21
Other Operating Expenses / (Income)		 0.13 -0.60 0.30 0.31 1.02 1.08 0.40 1.64 0.88 0.33
Total Other Income / (Expense), net		 0.10 0.12 0.11 0.15 -0.48 2.61 2.08 3.01 3.60 3.13
Interest & Investment Income		 - - 0.11 0.15 0.17 2.14 2.08 3.01 3.60 3.37
Basic Earnings per Share		 ($0.65) ($0.43) ($0.88) ($0.81) ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39)
Weighted Average Basic Shares Outstanding		 9.42M 8.40M 9.45M 10.42M 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M
Diluted Earnings per Share		 ($0.65) ($0.43) ($0.88) ($0.81) ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39)
Weighted Average Diluted Shares Outstanding		 9.42M 8.40M 9.45M 10.42M 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M
Weighted Average Basic & Diluted Shares Outstanding		 8.16M 8.17M 8.17M 9.99M 30.50M 32.46M 33.41M 38.87M 43.12M 45.86M

Annual Cash Flow Statements for Soleno Therapeutics

This table details how cash moves in and out of Soleno Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -2.46 -2.50 14 5.96 -2.37 28 -28 -6.70 155 -82
Net Cash From Operating Activities		 -10 -13 -9.95 -12 -17 -25 -28 -21 -25 -69
Net Cash From Continuing Operating Activities		 -10 -7.26 -6.92 -10 -17 -25 -28 -21 -25 -69
Net Income / (Loss) Continuing Operations		 -16 -6.74 -15 -12 -31 -25 -31 -24 -39 -176
Consolidated Net Income / (Loss)		 -16 -12 -15 -13 -31 -25 -31 -24 -39 -176
Depreciation Expense		 0.11 0.02 1.61 1.96 1.96 1.95 1.96 1.96 1.96 1.99
Amortization Expense		 - - - - - - - 0.00 0.00 -4.90
Non-Cash Adjustments To Reconcile Net Income		 4.69 -0.90 6.04 -0.77 11 -8.06 1.96 1.88 9.33 102
Changes in Operating Assets and Liabilities, net		 0.81 0.36 0.82 0.33 0.82 5.53 -0.78 -0.56 2.76 7.59
Net Cash From Investing Activities		 -1.32 -0.04 0.15 -0.18 0.53 -0.01 -0.02 -0.01 0.00 -226
Net Cash From Continuing Investing Activities		 -1.32 -0.01 -0.56 -0.01 0.53 -0.01 -0.02 -0.01 0.00 -226
Purchase of Property, Plant & Equipment		 -0.06 -0.01 -0.58 -0.01 -0.02 -0.01 -0.02 -0.01 0.00 -0.22
Purchase of Investments		 - - - - - - - 0.00 0.00 -356
Sale and/or Maturity of Investments		 - - - - - - - 0.00 0.00 131
Net Cash From Financing Activities		 9.16 11 24 18 14 54 -0.13 14 180 213
Net Cash From Continuing Financing Activities		 5.21 11 24 16 14 54 -0.13 14 180 213
Issuance of Debt		 0.10 - - - - - - 0.00 0.00 50
Issuance of Common Equity		 2.01 0.00 25 16 14 54 0.00 14 138 149
Other Financing Activities, net		 0.37 -0.05 -1.06 - 0.00 0.00 -0.13 -0.02 42 14

Quarterly Cash Flow Statements for Soleno Therapeutics

This table details how cash moves in and out of Soleno Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -4.31 -5.15 -6.73 11 33 117 -127 14 -8.61 40
Net Cash From Operating Activities		 -4.66 -5.14 -6.73 -5.57 -6.33 -6.31 -13 -18 -15 -24
Net Cash From Continuing Operating Activities		 -4.66 -5.14 -6.73 -5.57 -6.33 -6.31 -13 -18 -15 -24
Net Income / (Loss) Continuing Operations		 -6.13 -5.49 -8.36 -8.48 -11 -11 -21 -22 -77 -56
Consolidated Net Income / (Loss)		 -6.13 -5.49 -8.36 -8.48 -11 -11 -21 -22 -77 -56
Depreciation Expense		 0.49 0.49 0.49 0.49 0.49 0.49 0.49 0.49 0.50 0.50
Amortization Expense		 - - 0.00 - - - -0.47 -1.11 -1.91 -1.40
Non-Cash Adjustments To Reconcile Net Income		 0.67 0.39 1.32 1.56 3.71 2.74 5.92 8.34 57 30
Changes in Operating Assets and Liabilities, net		 0.32 -0.54 -0.18 0.86 0.33 1.75 2.94 -3.51 5.61 2.55
Net Cash From Investing Activities		 - -0.01 0.00 - - - -115 -121 4.04 6.44
Net Cash From Continuing Investing Activities		 - -0.01 0.00 - - - -115 -121 4.04 6.44
Purchase of Property, Plant & Equipment		 - -0.01 0.00 - - - -0.01 -0.01 -0.19 -0.01
Purchase of Investments		 - - 0.00 - - - -115 -146 -48 -48
Sale and/or Maturity of Investments		 - - - - - - - - 52 54
Net Cash From Financing Activities		 0.34 - 0.00 17 39 124 0.94 153 2.28 57
Net Cash From Continuing Financing Activities		 0.34 - 0.00 17 39 124 0.94 153 2.28 57
Issuance of Common Equity		 14 - - - 39 81 - - 5.05 -5.69
Other Financing Activities, net		 -14 - 0.00 - 0.01 42 0.94 3.16 -2.78 13

Annual Balance Sheets for Soleno Therapeutics

This table presents Soleno Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 8.20 5.56 39 43 38 65 36 26 181 331
Total Current Assets		 6.40 3.80 18 25 21 50 22 16 171 294
Cash & Equivalents		 5.49 2.73 17 23 21 49 21 15 170 88
Short-Term Investments		 - - - 0.98 - - - - 0.00 204
Prepaid Expenses		 0.17 0.25 0.34 0.53 0.41 1.02 1.12 1.05 1.68 2.45
Plant, Property, & Equipment, net		 0.09 0.04 0.02 0.01 0.02 0.02 0.03 0.03 0.01 0.19
Total Noncurrent Assets		 1.71 1.72 21 18 17 15 13 11 9.32 37
Long-Term Investments		 - - - - - - - - 0.00 27
Noncurrent Note & Lease Receivables		 - - - - 0.02 0.02 0.00 0.00 0.00 0.00
Intangible Assets		 0.08 - 20 18 17 15 13 11 8.75 6.81
Other Noncurrent Operating Assets		 0.72 0.13 0.13 - 0.46 0.12 0.46 0.13 0.57 2.88
Total Liabilities & Shareholders' Equity		 8.20 5.56 39 43 38 65 36 26 181 331
Total Liabilities		 4.98 2.13 12 13 23 19 18 16 23 86
Total Current Liabilities		 3.19 1.71 1.73 1.88 4.96 8.62 8.01 7.31 12 19
Accounts Payable		 0.70 0.41 0.63 0.93 2.00 3.49 3.25 1.78 3.15 8.88
Accrued Expenses		 1.63 1.05 0.97 0.32 2.00 3.79 3.42 3.22 3.39 1.83
Current Employee Benefit Liabilities		 - - - 0.27 0.28 1.01 0.73 1.68 3.14 4.78
Other Current Liabilities		 0.87 - - 0.35 0.69 0.34 0.61 0.64 1.83 3.26
Total Noncurrent Liabilities		 1.78 0.42 0.31 11 18 11 9.75 8.84 12 67
Long-Term Debt		 - - - - - - - - 0.00 50
Other Noncurrent Operating Liabilities		 1.78 0.34 0.08 11 18 11 9.75 8.84 12 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.22 3.44 27 30 15 46 18 10 158 245
Total Preferred & Common Equity		 3.22 3.44 27 30 15 46 18 10 158 245
Preferred Stock		 - - - - - - 0.00 0.00 0.00 0.00
Total Common Equity		 3.22 3.44 27 30 15 46 18 10 158 245
Common Stock		 89 102 141 157 173 228 231 248 434 697
Retained Earnings		 -86 -98 -114 -127 -158 -182 -213 -237 -276 -452
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - 0.00 0.36

Quarterly Balance Sheets for Soleno Therapeutics

This table presents Soleno Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 32 20 31 64 169 304 297
Total Current Assets		 21 9.13 20 54 151 268 258
Cash & Equivalents		 20 7.87 19 52 43 57 48
Short-Term Investments		 - - - - 107 209 208
Prepaid Expenses		 0.82 1.25 1.13 1.22 1.60 1.38 1.42
Plant, Property, & Equipment, net		 0.02 0.02 0.02 0.02 0.03 0.02 0.20
Total Noncurrent Assets		 11 10 10 9.87 18 37 38
Long-Term Investments		 - - - - 8.82 28 28
Intangible Assets		 11 10 9.72 9.24 8.26 7.78 7.29
Other Noncurrent Operating Assets		 0.21 0.18 0.71 0.64 0.50 0.35 3.08
Total Liabilities & Shareholders' Equity		 32 20 31 64 169 304 297
Total Liabilities		 17 17 19 40 25 23 32
Total Current Liabilities		 7.34 7.76 8.80 29 13 9.15 15
Accounts Payable		 2.32 2.78 3.44 3.22 8.02 3.72 6.24
Accrued Expenses		 2.83 3.53 3.47 3.24 2.40 1.86 1.76
Current Employee Benefit Liabilities		 1.28 0.72 1.17 1.50 1.23 2.15 3.41
Other Current Liabilities		 0.91 0.73 0.73 21 1.82 1.42 3.55
Total Noncurrent Liabilities		 9.44 9.14 9.72 11 12 14 17
Other Noncurrent Operating Liabilities		 9.44 9.14 9.72 11 12 14 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 2.64 12 23 143 281 265
Total Preferred & Common Equity		 15 2.64 12 23 143 281 265
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 2.64 12 23 143 281 265
Common Stock		 247 248 267 288 441 601 660
Retained Earnings		 -232 -246 -254 -265 -298 -320 -396
Accumulated Other Comprehensive Income / (Loss)		 -0.00 0.02 0.00 -0.00 -0.11 -0.15 0.90

Annual Metrics and Ratios for Soleno Therapeutics

This table displays calculated financial ratios and metrics derived from Soleno Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -219.14% 57.48% -76.08% 1.01% -141.96% 19.95% -27.60% 22.61% -76.80% -381.16%
EBIT Growth		 -74.66% 57.65% -99.51% -1.73% -121.54% 18.67% -25.45% 21.17% -70.58% -351.50%
NOPAT Growth		 -135.67% 31.54% -46.21% -17.50% -64.23% -54.51% 13.12% 22.62% -69.63% -353.49%
Net Income Growth		 -20.18% 24.16% -27.52% 13.32% -130.78% 19.94% -25.45% 22.14% -62.00% -351.04%
EPS Growth		 83.78% 24.16% 66.27% 62.57% -40.63% 56.67% -1,389.74% 50.60% 17.77% -85.59%
Operating Cash Flow Growth		 -129.67% -31.06% 26.29% -17.42% -48.72% -45.17% -10.09% 25.17% -20.01% -177.05%
Free Cash Flow Firm Growth		 -66.23% 3.31% -331.82% 109.85% -250.50% -537.10% 19.18% 26.54% -28.86% -469.33%
Invested Capital Growth		 -199.82% 39.80% 1,484.30% -67.03% -191.32% 36.45% 4.51% -21.16% -186.18% -94.73%
Revenue Q/Q Growth		 65.98% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.39% 49.02% -98.81% 26.93% -87.00% 34.16% 0.09% -15.24% -27.25% -35.65%
EBIT Q/Q Growth		 -6.64% 49.07% -92.09% 24.38% -77.05% 32.33% 0.07% -13.82% -25.64% -31.73%
NOPAT Q/Q Growth		 -15.82% 30.82% -79.78% 10.42% -15.87% -3.43% 13.58% -11.97% -25.09% -31.73%
Net Income Q/Q Growth		 21.56% 1.89% -16.07% 27.29% -93.72% 32.33% 0.08% -12.42% -17.51% -34.07%
EPS Q/Q Growth		 16.34% 1.89% 2.29% 25.58% -80.00% 17.02% -228.25% 55.64% 23.13% -61.62%
Operating Cash Flow Q/Q Growth		 -21.49% 4.86% -0.43% -9.40% -8.36% -7.64% 0.01% 7.64% -4.93% -34.38%
Free Cash Flow Firm Q/Q Growth		 0.00% 45.64% -38.05% 212.39% 67.59% -115.47% 13.44% 12.57% -1,496.55% -10.02%
Invested Capital Q/Q Growth		 38.05% -629.82% 15.62% 39.99% -258.09% 54.78% 56.01% 6.53% 58.33% -18.40%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 41.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -2,601.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -2,001.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -2,618.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -2,618.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 179.07% 114.45% 112.62% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 86.59% 101.58% 100.00% 100.00% 98.77% 93.80% 93.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 399.40% -362.37% -101.71% -46.60% -135.69% -81.46% -97.60% -171.05% -46.45% -87.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -151.56% 22.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -191.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -191.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 399.40% -362.37% -101.71% -46.60% -135.69% -81.46% -97.60% -171.05% -46.45% -87.35%
Return on Equity Simple (ROE_SIMPLE)		 -493.47% -351.22% -57.37% -43.85% -205.89% -54.10% -173.72% -232.58% -24.75% -71.74%
Net Operating Profit after Tax (NOPAT)		 -8.51 -5.83 -8.52 -10 -16 -25 -22 -17 -29 -131
NOPAT Margin		 -1,401.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 302.44% -120.51% -110.51% -20.99% -63.98% 2.18% -25.07% -38.93% -10.87% -20.29%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -165.04% -18.39% -44.54%
Cost of Revenue to Revenue		 58.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,010.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 746.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 2,043.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -6.74 -13 -14 -30 -25 -31 -24 -42 -188
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -6.72 -12 -12 -28 -23 -29 -22 -40 -191
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.04 0.08 0.59 0.22 0.12 1.56 7.79 7.91
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.19 0.20 0.00 0.33 0.42 0.00 8.25 8.13
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20
Financial Leverage		 -0.61 -1.55 -0.41 -0.55 -0.99 -1.16 -1.11 -1.28 -1.10 -1.09
Leverage Ratio		 -2.08 2.07 1.47 1.44 1.79 1.71 1.59 2.21 1.23 1.27
Compound Leverage Factor		 -2.08 2.07 1.47 1.24 1.82 1.71 1.59 2.18 1.16 1.19
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.89%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.89%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 83.11%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.41
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.38
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.05
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.38
Altman Z-Score		 0.00 0.00 -4.66 -4.42 -7.67 -4.10 -10.71 -14.60 29.93 10.76
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 2.01 2.23 10.38 13.14 4.26 5.83 2.80 2.14 14.89 15.68
Quick Ratio		 1.77 1.60 9.87 12.86 4.18 5.71 2.66 2.00 14.75 15.55
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.98 -6.74 -29 2.87 -4.32 -28 -22 -16 -21 -120
Operating Cash Flow to CapEx		 -18,465.19% -91,233.39% -1,730.43% -146,037.50% -82,738.10% -360,342.86% -126,227.27% -159,853.85% 0.00% -31,695.41%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -518.77
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -299.12
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -300.06
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 1.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 8.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 341.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 870.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -528.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -2.31 -1.39 19 6.34 -5.79 -3.68 -3.51 -4.25 -12 -24
Invested Capital Turnover		 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.54 0.92 21 -13 -12 2.11 0.17 -0.74 -7.92 -12
Enterprise Value (EV)		 0.00 0.00 -16 -22 -12 -39 -19 1.55 1,058 1,669
Market Capitalization		 0.00 0.00 1.20 2.44 8.75 10 2.18 16 1,228 1,938
Book Value per Share		 $0.26 $0.22 $2.68 $1.42 $0.44 $0.57 $0.22 $1.27 $5.16 $5.68
Tangible Book Value per Share		 $0.18 $0.22 $0.64 $0.56 ($0.05) $0.39 $0.06 ($0.04) $4.88 $5.53
Total Capital		 3.22 3.44 27 30 15 46 18 10 158 295
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50
Net Debt		 -5.53 -2.76 -17 -24 -21 -49 -21 -15 -170 -269
Capital Expenditures (CapEx)		 0.06 0.01 0.58 0.01 0.02 0.01 0.02 0.01 0.00 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.32 -0.67 -0.87 -1.28 -4.55 -7.60 -6.89 -6.27 -9.83 -16
Debt-free Net Working Capital (DFNWC)		 3.21 2.09 16 23 16 42 14 8.33 160 275
Net Working Capital (NWC)		 3.21 2.09 16 23 16 42 14 8.33 160 275
Net Nonoperating Expense (NNE)		 7.40 6.24 6.87 3.32 14 -0.76 8.84 6.99 10 44
Net Nonoperating Obligations (NNO)		 -5.53 -4.82 -7.60 -24 -21 -49 -21 -15 -170 -269
Total Depreciation and Amortization (D&A)		 0.11 0.02 1.61 1.96 1.96 1.95 1.96 1.96 1.96 -2.91
Debt-free, Cash-free Net Working Capital to Revenue		 -381.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 528.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 528.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($126.75) ($75.75) ($26.25) ($9.60) ($13.50) ($5.85) ($5.85) ($2.87) ($2.36) ($4.38)
Adjusted Weighted Average Basic Shares Outstanding		 205.40K 633.07K 1.30M 2.12M 2.98M 5.31M 5.34M 8.40M 16.49M 40.18M
Adjusted Diluted Earnings per Share		 ($126.75) ($75.75) ($26.25) ($9.60) ($13.50) ($5.85) ($5.85) ($2.87) ($2.36) ($4.38)
Adjusted Weighted Average Diluted Shares Outstanding		 205.40K 633.07K 1.30M 2.12M 2.98M 5.31M 5.34M 8.40M 16.49M 40.18M
Adjusted Basic & Diluted Earnings per Share		 ($126.75) ($75.75) ($26.25) ($9.60) ($13.50) ($5.85) ($5.85) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 125.68K 206.77K 598.52K 1.40M 2.28M 4.17M 5.32M 8.17M 32.46M 45.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.51 -5.83 -8.52 -10 -16 -25 -22 -17 -29 -131
Normalized NOPAT Margin		 -1,401.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -2,618.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -812.43
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -568.70
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -813.37
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -569.64
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Soleno Therapeutics

This table displays calculated financial ratios and metrics derived from Soleno Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 26.26% -126.80% -52.50% -30.48% -86.97% -153.32% -194.00% -213.38% -674.03% -347.16%
EBIT Growth		 24.67% -104.60% -47.96% -28.21% -79.96% -140.41% -177.19% -188.43% -626.89% -324.99%
NOPAT Growth		 24.75% -86.94% -46.70% -27.20% -66.51% -147.95% -177.19% -188.39% -672.61% -324.99%
Net Income Growth		 24.67% -93.99% -45.98% -26.02% -77.12% -105.91% -156.08% -157.86% -605.42% -395.59%
EPS Growth		 57.52% 89.33% 17.76% -12.50% -46.15% 165.12% 32.95% 29.63% -92.63% -596.43%
Operating Cash Flow Growth		 13.87% 25.06% -5.75% -20.48% -36.00% -22.77% -86.21% -217.12% -135.72% -279.97%
Free Cash Flow Firm Growth		 -31.03% -40.47% 44.61% 60.11% 323.19% 42.93% -111.22% -268.34% -475.57% -1,542.72%
Invested Capital Growth		 42.98% -21.16% -115.08% -84.78% -541.99% -186.18% -187.72% -99.48% 31.47% -94.73%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 9.51% 6.06% -59.64% -1.93% -29.66% -27.27% -74.79% -8.65% -220.25% 26.47%
EBIT Q/Q Growth		 8.82% 5.64% -54.37% -1.81% -27.99% -26.05% -68.76% -5.93% -222.55% 26.30%
NOPAT Q/Q Growth		 8.02% 10.02% -50.96% -1.82% -20.40% -33.98% -68.76% -5.93% -222.55% 26.30%
Net Income Q/Q Growth		 8.82% 10.53% -52.32% -1.42% -28.15% -4.01% -89.43% -2.13% -250.58% 26.93%
EPS Q/Q Growth		 9.72% 33.85% -104.65% 7.95% -17.28% 129.47% -310.71% 3.39% -221.05% 24.04%
Operating Cash Flow Q/Q Growth		 -0.78% -10.46% -30.82% 17.27% -13.76% 0.28% -98.42% -40.89% 15.44% -60.73%
Free Cash Flow Firm Q/Q Growth		 -9.07% 59.16% 1.78% 8.83% 710.24% -110.44% -263.54% -58.98% -522.22% 54.32%
Invested Capital Q/Q Growth		 -21.13% 6.53% -23.06% -32.61% -320.87% 58.33% -23.72% 8.06% -44.58% -18.40%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 94.82% 98.67% 98.30% 98.42% 81.21% 91.15% 87.88% 95.52% 94.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -120.94% -171.05% -183.50% -173.82% -172.71% -46.45% -71.26% -44.62% -91.11% -87.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -120.94% -171.05% -183.50% -173.82% -172.71% -46.45% -71.26% -44.62% -91.11% -87.35%
Return on Equity Simple (ROE_SIMPLE)		 -140.85% 0.00% -1,011.71% -228.95% -142.89% 0.00% -36.29% -23.30% -49.55% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.36 -3.93 -5.93 -6.04 -7.27 -9.74 -16 -17 -56 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.37% -8.68% -13.21% -11.23% -9.96% -1.69% -5.97% -2.83% -12.14% -6.66%
Return On Investment Capital (ROIC_SIMPLE)		 - -37.95% - - - -6.18% - - - -14.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.13 -5.79 -8.47 -8.62 -11 -14 -23 -25 -80 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.64 -5.30 -7.98 -8.13 -11 -13 -23 -25 -82 -60
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.89 1.56 6.62 2.82 12.70 7.79 9.69 4.86 7.41 7.91
Price to Tangible Book Value (P/TBV)		 3.36 0.00 0.00 12.96 21.08 8.25 10.28 4.99 7.62 8.13
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 160.85 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20
Financial Leverage		 -1.35 -1.28 -1.26 -1.33 -1.88 -1.10 -1.14 -1.07 -1.17 -1.09
Leverage Ratio		 2.11 2.21 2.13 2.07 2.49 1.23 1.29 1.14 1.25 1.27
Compound Leverage Factor		 2.11 2.09 2.10 2.04 2.45 1.00 1.18 1.00 1.20 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.89%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.89%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 83.11%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.41
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.38
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.05
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.38
Altman Z-Score		 -9.81 -12.29 -18.34 -10.83 -1.56 30.44 30.80 34.27 35.01 12.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 2.80 2.14 1.18 2.33 1.85 14.89 11.23 29.24 17.26 15.68
Quick Ratio		 2.69 2.00 1.01 2.20 1.81 14.75 11.11 29.08 17.16 15.55
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.80 -3.18 -3.13 -2.85 17 -1.82 -6.61 -11 -65 -30
Operating Cash Flow to CapEx		 0.00% -85,716.67% 0.00% 0.00% 0.00% 0.00% -113,890.91% -220,637.50% -7,814.66% -299,887.50%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -4.55 -4.25 -5.24 -6.94 -29 -12 -15 -14 -20 -24
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.43 -0.74 -2.80 -3.19 -25 -7.92 -9.83 -6.91 9.20 -12
Enterprise Value (EV)		 -6.22 1.55 9.61 16 242 1,058 1,231 1,069 1,678 1,669
Market Capitalization		 14 16 17 35 295 1,228 1,389 1,363 1,963 1,938
Book Value per Share		 $0.13 $1.27 $0.32 $1.52 $2.32 $5.16 $4.42 $8.40 $6.81 $5.68
Tangible Book Value per Share		 $0.03 ($0.04) ($0.93) $0.33 $1.40 $4.88 $4.16 $8.17 $6.62 $5.53
Total Capital		 15 10 2.64 12 23 158 143 281 265 295
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50
Net Debt		 -20 -15 -7.87 -19 -52 -170 -158 -295 -285 -269
Capital Expenditures (CapEx)		 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.19 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.52 -6.27 -6.51 -7.67 -28 -9.83 -12 -7.77 -14 -16
Debt-free Net Working Capital (DFNWC)		 13 8.33 1.37 12 25 160 138 258 243 275
Net Working Capital (NWC)		 13 8.33 1.37 12 25 160 138 258 243 275
Net Nonoperating Expense (NNE)		 1.77 1.56 2.43 2.44 3.59 1.56 4.97 4.45 20 15
Net Nonoperating Obligations (NNO)		 -20 -15 -7.87 -19 -52 -170 -158 -295 -285 -269
Total Depreciation and Amortization (D&A)		 0.49 0.49 0.49 0.49 0.49 0.49 0.02 -0.62 -1.41 -0.90
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.76) ($0.43) ($0.88) ($0.81) ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39)
Adjusted Weighted Average Basic Shares Outstanding		 8.09M 8.40M 9.45M 10.42M 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M
Adjusted Diluted Earnings per Share		 ($0.76) ($0.43) ($0.88) ($0.81) ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39)
Adjusted Weighted Average Diluted Shares Outstanding		 8.09M 8.40M 9.45M 10.42M 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.16M 8.17M 8.17M 9.99M 30.50M 32.46M 33.41M 38.87M 43.12M 45.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.36 -3.93 -5.93 -6.04 -7.27 -9.74 -16 -17 -56 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Soleno Therapeutics' Financials

When does Soleno Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Soleno Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Soleno Therapeutics' net income changed over the last 9 years?

Soleno Therapeutics' net income appears to be on an upward trend, with a most recent value of -$175.85 million in 2024, rising from -$15.91 million in 2015. The previous period was -$38.99 million in 2023.

What is Soleno Therapeutics's operating income?
Soleno Therapeutics's total operating income in 2024 was -$187.67 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $187.67 million
How has Soleno Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Soleno Therapeutics' total revenue changed from $607.47 thousand in 2015 to $0.00 in 2024, a change of -100.0%.

How much debt does Soleno Therapeutics have?

Soleno Therapeutics' total liabilities were at $85.86 million at the end of 2024, a 270.3% increase from 2023, and a 1,625.0% increase since 2015.

How much cash does Soleno Therapeutics have?

In the past 9 years, Soleno Therapeutics' cash and equivalents has ranged from $2.73 million in 2016 to $169.68 million in 2023, and is currently $87.93 million as of their latest financial filing in 2024.

How has Soleno Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Soleno Therapeutics' book value per share changed from 0.26 in 2015 to 5.68 in 2024, a change of 2,080.6%.


Related Companies

This page (NASDAQ:SLNO) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...
Altimetry | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
China’s next move could destroy U.S. tech
The U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...
Investors Alley | Sponsored
This isn’t a trade war. It’s worse…
Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...
Stansberry Research | Sponsored
Trump Makes Major Crypto Announcement
Trump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...
Crypto 101 Media | Sponsored